Update on pneumococcal vaccination in adults
Article Sidebar
Main Article Content
Abstract
The Streptococcus pneumoniae invasive disease is a major cause of morbidity and mortality, being the leading cause of vaccine-preventable death in the world, not only in children but in all ages. Both the polysaccharide vaccine and pneumococcal conjugate vaccine have shown reduced rates of invasive disease in adults. In recent years, in light of new evidence available, schedules of pneumococcal vaccination for this population have changed. This document provides an update on vaccine recommendations through the rational that have led to this change
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25 DOI: https://doi.org/10.1056/NEJMoa1408544
Butler JC, Shapiro ED, Carlone GM. Pneumococcal vaccines: history, current status, and future directions. Am J Med. 1999;107(1A):69S-76S DOI: https://doi.org/10.1016/S0002-9343(99)00105-9
Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis. 2009;49(9):1318-25. DOI: https://doi.org/10.1086/606046
Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31(35):3585-93. DOI: https://doi.org/10.1016/j.vaccine.2013.05.010
Lopardo G, Basombrío A, Clara L, et al. [Guidelines for management of community-acquired pneumonia in adults]. Medicina (B Aires). 2015;75(4):245-57.
Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;(1):CD000422. DOI: https://doi.org/10.1002/14651858.CD000422.pub2
Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822-5.
Domínguez V, Arrazola P. Sociedad Española de Medicina Preventiva, Salud Pública e Higiene: Recomendaciones de Vacunación Antineumocócica en el Adulto por Indicación Médica 2012. http//www.sempsph.com. Acceso 10/2015.
Fossati S, et al. Invasive pneumococcal disease among adults in Argentina (2010-2012): serotype distribution, antibiotic resistance and vaccine serotype coverage. Presentado en 9th International Symposium on Pneumococci and Pneumococcal Diseases. March 9-13, 2014. Hyderabad, India.
Gabastou JM, et al. Informe Regional de SIREVA II, 2012: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores. OPS, 2013.
Vacunación contra neumococo en adultos. Boletín Informativo, Comisión de Vacunas, Sociedad Argentina de Infectología. Agosto de 2015.